Picture EBD Group BioPharm Amercia 2022 Boston 650x100px

Organisation › Details

Bristol-Myers Squibb GmbH & Co. KGaA (BMS)

https://www.bms.com/de

	Start	1995-01-01 existent
	Group	Bristol-Myers Squibb (BMS) (Group)
	Industry	pharmaceutical

	Region	München (Munich)
	Country	Germany
	Street	29 Arnulfstr.
	City	80636 München
	Tel	+49-89-12142-0
		Address record changed: 2020-12-02

Basic data	Employees	E: 501 to 1,000 (2006-01-01)


		Record changed: 2022-03-21

Picture Berlin Partner Health Capital Computational Biology 2022 650x200px

More documents for Bristol-Myers Squibb (BMS) (Group)

[1] Bristol-Myers Squibb Company. (6/3/22). "Press Release: Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company". New York, NY & San Diego, CA....
[2] Immatics N.V.. (6/2/22). "Press Release: Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs". Tübingen, Houston, TX & New York, NY....
[3] Evotec SE. (5/10/22). "Press Release: Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation". Hamburg....
[4] Temedica GmbH. (3/15/22). "Press Release: Temedica Announces Cooperation with Bristol Myers Squibb for the Development of a Digital Companion for Psoriasis Patients". Munich....
[5] Immatics N.V.. (12/14/21). "Press Release: Immatics and Bristol Myers Squibb Enter into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401". Tübingen, Houston, TX & New York, NY....
[6] Evotec SE. (10/8/21). "Press Release: Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include Novel Cell Type". Hamburg....
[7] Cardior Pharmaceuticals GmbH. (8/25/21). "Press Release: Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease". Hanover....
[8] Bristol-Myers Squibb Company. (8/19/21). "Press Release: Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma". Princeton, NJ....
[9] Exscientia Ltd.. (8/18/21). "Press Release: Bristol Myers Squibb Exercises Option to Develop Exscientia’s AI-designed, Immune-modulating Drug Candidate". Oxford....
[10] Be Biopharma, Inc.. (8/11/21). "Press Release: Be Bio Appoints Leading Cell & Gene Therapy Executives, Krishnan Viswanadhan as President & Chief Operating Officer, and Brad Hartman as Chief People Officer". Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]